US · Healthcare · Biotechnology
EPS came in at -0.48 against a street estimate of -0.41 — a miss of 17.1%.
Analysts rate Aura Biosciences Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $16.60.
| Fund | Stake |
|---|---|
| TCG Crossover Management, LLC | 9.19% |
| Matrix Capital Management Company, LLC | 6.68% |
| Long Focus Capital Management, LLC | 4.94% |
| Frazier Life Sciences Management, L.P. | 4.92% |
| Adage Capital Partners Gp LLC | 4.47% |
| Suvretta Capital Management, LLC | 4.22% |
| Caligan Partners LP | 4.14% |
| BlackRock Inc | 3.46% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 AURA BIOSCIENCES, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash Position: $67.8 million in cash and cash equivalents as of June 30, 2026, up | 2026-08-11 |
| Results announced · Q3 2026 AURA BIOSCIENCES Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $323.8 million (cash, cash equivalents, and marketable securiti | 2026-08-11 |
| Shareholder vote results · Q3 2026 AURA BIOSCIENCES, INC. — 8-K SUMMARY HEADLINE NUMBERS • Company held Special Meeting of Stockholders on August 5, 2026 • Record date: June 12, 2026 | 2026-08-05 |
| Board / officer change · Q3 2026 AURA BIOSCIENCES, INC. (NASDAQ: AURA) – 8-K FILING SUMMARY HEADLINE NUMBERS • Board size increased from 6 to 7 directors • New director appointed ef | 2026-07-08 |
| Proxy statement · Q3 2026 AURA BIOSCIENCES, INC. – PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Increase authorized common stock shares from 150,000,000 to 500 | 2026-06-29 |
| Shareholder vote results · Q2 2026 AURA BIOSCIENCES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 11, 2026 • Total shares entitled to vote: 64,199,778 • Shares prese | 2026-06-11 |
| Quarterly report · Q1 2026 AURA BIOSCIENCES, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $84.8 million in cash and cash equivalents as of March 31, 2026 (dow | 2026-05-11 |
| Proxy statement · Q2 2026 AURA BIOSCIENCES, INC. — 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 (Election of Directors): Elect two Class II direc | 2026-04-20 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aura Biosciences Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.